CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Sees Large Increase in Short Interest

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) saw a large growth in short interest in August. As of August 31st, there was short interest totalling 202,500 shares, a growth of 87.7% from the August 15th total of 107,900 shares. Based on an average daily volume of 5,550,000 shares, the days-to-cover ratio is presently 0.0 days.

Hedge Funds Weigh In On CNS Pharmaceuticals

A hedge fund recently bought a new stake in CNS Pharmaceuticals stock. Armistice Capital LLC purchased a new position in shares of CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 122,000 shares of the company’s stock, valued at approximately $155,000. Armistice Capital LLC owned approximately 1.96% of CNS Pharmaceuticals at the end of the most recent reporting period. 14.02% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Maxim Group raised CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research note on Tuesday, September 10th.

CNS Pharmaceuticals Price Performance

Shares of CNSP stock remained flat at $0.15 on Friday. The stock had a trading volume of 1,423,750 shares, compared to its average volume of 2,074,843. The stock has a market cap of $213,852.60, a price-to-earnings ratio of 0.00 and a beta of 2.58. The business has a fifty day moving average of $0.48 and a 200-day moving average of $7.25. CNS Pharmaceuticals has a 52 week low of $0.10 and a 52 week high of $137.50.

CNS Pharmaceuticals (NASDAQ:CNSP) last released its earnings results on Wednesday, August 14th. The company reported ($6.72) earnings per share (EPS) for the quarter.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.